← Back to Search

Procedure

Surgical Procedures for Early-Stage Lung Cancer

Phase 3
Waitlist Available
Research Sponsored by Alliance for Clinical Trials in Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No prior chemotherapy or radiation therapy for this malignancy
ECOG performance status of 0-2
Must not have
Pure ground glass opacities or pathologically confirmed N1 or N2 disease
Node levels 4, 7, and 10 not diagnosed as negative on frozen section for right sided tumors
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is comparing wedge resection, segmentectomy, and lobectomy to see which is more effective in treating stage IA non-small cell lung cancer.

Who is the study for?
This trial is for adults over 18 with early-stage IA non-small cell lung cancer. Candidates should have a small lung nodule presumed to be cancer, located in the outer part of the lung, and no advanced or metastatic disease. They must not have had other cancers (except certain skin, bladder, or cervical cancers) in the past 3 years and no prior treatments for this cancer.
What is being tested?
The study is comparing two less invasive surgical methods—segmentectomy or wedge resection—with lobectomy to see which one works better for stage IA non-small cell lung cancer. Patients will be randomly assigned to undergo one of these surgeries.
What are the potential side effects?
Potential side effects from these surgeries may include pain at the surgery site, shortness of breath, fatigue during recovery, risk of infection, and complications related to anesthesia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I haven't had chemotherapy or radiation for my cancer.
Select...
I can take care of myself and am up and about more than half of the day.
Select...
My lung nodule is 2 cm or smaller, located on the outer part of my lung, and presumed to be cancer.
Select...
My cancer has not spread beyond its original location.
Select...
My tumor can be removed by surgery.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My lung scans show ground glass opacities or I have N1 or N2 lung cancer.
Select...
My right-sided tumor's nodes 4, 7, and 10 were not confirmed negative.
Select...
My left-sided tumor's lymph nodes at levels 5, 6, 7, and 10 were not confirmed negative.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm BExperimental Treatment1 Intervention
Patents undergo a limited resection (segentectomy or wedge resection), which a smaller portion of the lung is removed.
Group II: Arm AExperimental Treatment1 Intervention
Patients undergo a standard operation for lung cancer called a lobectomy.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,111,386 Total Patients Enrolled
Alliance for Clinical Trials in OncologyLead Sponsor
518 Previous Clinical Trials
221,636 Total Patients Enrolled
Nasser Altorki, MDStudy ChairWeill Medical College of Cornell University

Media Library

Lobectomy (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT00499330 — Phase 3
Lung Cancer Research Study Groups: Arm B, Arm A
Lung Cancer Clinical Trial 2023: Lobectomy Highlights & Side Effects. Trial Name: NCT00499330 — Phase 3
Lobectomy (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00499330 — Phase 3
~29 spots leftby Sep 2025